1531 GMT - Novo Nordisk's trial of CagriSema in obese patients with diabetes demonstrated 13.7% weight loss, below investor expectations of around 15% and broadly in line with Eli Lilly's Zepbound drug, Bank of America Securities analysts Sachin Jain and Graham Parry write. The drug had already disappointed in a trial of patients without diabetes. The bank had seen potential for CagriSema to demonstrate superior weight loss to Zepbound, but the difference between the drug's effect on obese patients and obese diabetic patients looks very similar to both Novo Nordisk's current Semaglutide drug and Zepbound. The data therefore unlikely changes the CagriSema debates around commercial positioning and its insufficient differentiation versus high-dose Semaglutide, among others, they say. Shares fall 2.9%. (dominic.chopping@wsj.com)
(END) Dow Jones Newswires
March 11, 2025 11:31 ET (15:31 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.